Testosterone Augmentation for Depression: When It’s a Real Option, and When It Isn’t

Published: May 2026 | By: Dr. Baghel | Category: Adult Psychiatry

When a man comes in still depressed after one or two antidepressant trials, low testosterone is one of the things worth checking. Most of these men have never had a level drawn. In the subset whose workup confirms hypogonadism, treating the hormone can be part of how the depression finally lifts. The clinical work is figuring out which men actually fit that picture.

When he is already on an antidepressant, adding testosterone brings its own monitoring questions, which I cover in running TRT alongside an antidepressant.

Testosterone is one of several things worth checking when an antidepressant isn’t working. I walk through the fuller decision tree, dosing adequacy, diagnosis, and augmentation choices, in my guide to what to do when your antidepressant isn’t working.

Hormones are one metabolic factor among several in depression, a theme I develop in metabolic psychiatry.

Testosterone is one piece of a larger picture, which I cover in my guide to balancing hormones and mental health.

On the hormone side, see my guide to testosterone therapy for North Carolina men.

I’m Dr. Baghel, a board-certified psychiatrist who also manages testosterone therapy. I see this exact crossover several times a week, which is the reason for this piece. Below is what augmentation actually means, where the evidence lands, who’s a candidate, who isn’t, and what to expect if testosterone ends up in the plan.

For men in North Carolina considering whether their depression has a hormonal piece worth checking, an evaluation that looks at both is available by telehealth.

---

What Testosterone Augmentation for Depression Actually Means

In psychiatry, augmentation is adding a second agent to an antidepressant that’s helping but not enough. It’s a recognized strategy when monotherapy produces partial response, and the major guidelines and trial data lay out a standard menu.

The well-established augmentations include lithium, an atypical antipsychotic such as aripiprazole or quetiapine, liothyronine (T4 conversion to T3), and combining classes such as bupropion or mirtazapine with an SSRI. When two adequate trials have failed and depression meets criteria for treatment-resistant, procedural options including esketamine and TMS come into the conversation, both of which sit in their own decision-making layer covered in the practice’s piece on treatment-resistant depression.

Testosterone isn’t on the standard augmentation menu in CANMAT, NICE, or STAR*D. In clinical practice, it’s used off-label in a specific subset: men with low testosterone whose depression hasn’t fully responded to standard treatment. The literature for that subset is small but consistent, and it earns testosterone a place in the augmentation conversation when the workup justifies it.

Where Testosterone Fits in the Augmentation Menu

Testosterone’s role in depression is narrow, and the framing matters. Testosterone is approved by the FDA to treat hypogonadism, the medical condition of low testosterone with symptoms. It is not approved as an antidepressant. Using testosterone to address depressive symptoms in a man with confirmed hypogonadism is off-label use, which is a routine part of clinical medicine when the evidence supports it.

The case for testosterone as augmentation rests on a specific clinical picture: a man with confirmed low testosterone, classic hypogonadal symptoms (low libido, loss of morning erections, fatigue, reduced muscle mass, increased central adiposity), and depressive symptoms that haven’t fully cleared on adequate antidepressant treatment. In that man, treating the hypogonadism often improves mood as part of the broader response.

For men with normal testosterone, augmentation with testosterone may not produce a meaningful antidepressant effect, the evidence on that is clear, and supraphysiologic levels carry their own psychiatric risks including mood instability and aggression. The biology that makes testosterone useful in deficiency also makes it harmful in excess.

What the Evidence Actually Shows

The augmentation literature is small but it points the same direction. Four studies carry most of the weight.

A 2019 meta-analysis in JAMA Psychiatry by Walther and colleagues pooled randomized trials of testosterone treatment in men and found a significant reduction in depressive symptoms, with an odds ratio of 2.30 for treatment response. The effect was strongest with higher-dosage regimens, and the trials varied widely in design and population. The takeaway is positive in confirmed low T, less generalizable to all comers.

A randomized, placebo-controlled trial by Pope and colleagues at McLean Hospital studied testosterone gel in depressed men with low testosterone who hadn’t responded well to antidepressants. The treated group showed significantly greater improvement on the Hamilton Depression Rating Scale than placebo. The authors called the findings preliminary, and they were, with a small sample and short duration. The direction matched the biology.

A separate placebo-controlled trial by Shores and colleagues tested testosterone gel in hypogonadal older men with subthreshold depression (dysthymia or minor depression). After 12 weeks, the testosterone group reached 52.9% remission compared with 18.8% in the placebo group, with significantly greater HAM-D improvement. This is the cleanest signal in the literature, and it’s specifically in confirmed low T plus persistent low-grade depressive symptoms.

The augmentation question was tested directly by Seidman and Rabkin in hypogonadal men whose depression had failed to respond to SSRI treatment. The authors concluded that testosterone replacement “may be an effective augmentation treatment” in that population. The sample was small. The signal was real.

Taken together, the studies support a narrow, defensible claim: in men with confirmed low testosterone whose depression is incompletely treated, adding testosterone may improve depressive symptoms as part of treating the underlying hypogonadism. The literature does not support testosterone as a general antidepressant augmentation strategy in men with normal levels, and the studies that exist are mostly small and short.

The Lab Workup That Has to Come First

Augmentation decisions only make sense after the workup, and the workup is where most of these conversations should start. The fuller version lives in the practice’s article on low testosterone and depression, but the essentials are worth restating.

Morning blood draw. Testosterone follows a daily rhythm, peaking early, so an afternoon level can read falsely low. Confirm a low value with a repeat morning measurement before calling it low, per the Endocrine Society guideline. One reading isn’t enough.

Measure total testosterone, free testosterone when SHBG is altered, and SHBG, LH, and FSH together to distinguish primary from secondary hypogonadism. Check thyroid, vitamin D, B12, a metabolic panel, and a blood count at the same visit, because the conditions that mimic depression cluster together. A man whose “low T” turns out to be a thyroid problem doesn’t need testosterone, he needs thyroid treatment.

The numbers don’t replace clinical judgment. A total testosterone just below a lab cutoff in an asymptomatic man means something different from a clearly low level with classic symptoms.

When Testosterone Augmentation Makes Sense

A few conditions need to be met before adding testosterone to a depression plan is the right move.

Testosterone is confirmed low on repeat morning testing, with free testosterone consistent or with clear hypogonadal symptoms. The patient has had an adequate antidepressant trial, at therapeutic dose for at least six weeks, with consistent adherence, and the response is partial rather than absent. Physical features of hypogonadism are present, not just generalized fatigue. The patient understands and accepts the monitoring requirements, including periodic lab work and adjustments. There are no contraindications such as untreated prostate cancer, severe untreated polycythemia, or unstable cardiovascular disease.

When those conditions line up, adding testosterone as part of treating the hypogonadism is a reasonable clinical decision, and mood improvement is one of the things to monitor for over the first 8 to 12 weeks.

When It Doesn’t, and Why That Matters

Most men who ask me about testosterone augmentation should not start testosterone. That sentence is the most important one in this piece. Several scenarios call for not augmenting, and each one matters because the wrong call leads either to taking on a long-term hormone therapy that doesn’t help or to missing the actual diagnosis.

Normal testosterone levels close the conversation. Testosterone for a man whose levels are normal is supplementation, not treatment, and it produces no antidepressant benefit while carrying real risks.

Inadequate prior treatment is another stop sign. A man who was prescribed sertraline two weeks ago and stopped because it didn’t work hasn’t had a real antidepressant trial. The right next step is an adequate trial, not testosterone.

Unrecognized bipolar II is the differential to keep checking. Depression that hasn’t responded to multiple SSRIs in a man with any history of high-energy, low-sleep, impulsive periods may not be unipolar depression, and antidepressant augmentation of any kind, including testosterone, can destabilize mood in bipolar spectrum patients.

SSRI sexual side effects can look exactly like low testosterone, including in men with normal levels. Sorting those apart requires lab work and clinical history, including whether the libido and erectile changes began before or after the SSRI. Some men develop post-SSRI sexual dysfunction that persists after the drug is stopped, which is its own clinical territory.

Fertility plans matter. Testosterone suppresses sperm production, often substantially, and reversal isn’t guaranteed. Younger men, or men hoping to have biological children, need an explicit conversation about that trade-off before starting, and there are usually better routes to address mood without ending fertility.

The Risks and the Monitoring Burden

Testosterone therapy is a medical commitment. The risks are manageable under physician supervision, and they’re real enough that this is not a treatment to manage casually.

Hematocrit rises, which requires regular blood counts and sometimes dose adjustment or therapeutic phlebotomy. Sperm production drops. Acne and breast tissue changes can develop. The full set of side effects lives in the practice’s piece on TRT side effects and how monitoring works.

On cardiovascular safety, the 2023 TRAVERSE trial randomized over 5,000 hypogonadal men with high cardiovascular risk and found testosterone noninferior to placebo for major cardiac events. That’s reassurance for the population the FDA approves it for, with appropriate monitoring.

On regulatory scope, the FDA approves testosterone for hypogonadism caused by medical conditions and has been explicit that its safety and benefit are not established for low testosterone due to aging alone. A confirmed diagnosis is the line, and chasing a number into the high-normal range for mood reasons crosses it.

Getting Evaluated in North Carolina

The reason this evaluation rarely gets done well is that the depression workup and the hormonal workup usually happen in different offices, billed to different specialties, with neither side seeing the whole man. Patients end up with an antidepressant from psychiatry that didn’t fully work, then a testosterone prescription from an online TRT clinic that never asked about their mental health, and the plan isn’t actually a plan.

Baghel Psychiatry handles both. A single appointment evaluates the depression and the hormonal picture together, the labs that get ordered are the ones the literature actually supports, and the augmentation decision is made by one physician with both pieces of information in view. The broader framework for depression treatment in North Carolina covers the rest of the plan, and testosterone replacement therapy is managed under the same roof when it’s clinically indicated. The practice is telehealth across North Carolina, cash-pay, no insurance billing, with set monthly pricing.

---

Frequently Asked Questions

Is testosterone augmentation a recognized treatment for depression?

Major guidelines like CANMAT and NICE list lithium, atypical antipsychotics, liothyronine, and combination strategies as standard augmentations, not testosterone, and the FDA approves testosterone for hypogonadism rather than depression. The off-label clinical use is real and has support from several randomized trials including Pope 2003, Shores 2009, and Seidman/Rabkin 1998 in men with confirmed low testosterone whose depression hasn’t fully responded to standard antidepressants. Off-label use is common in medicine; the test is whether the evidence and the patient profile justify it.

Does testosterone work for depression if my testosterone level is normal?

The evidence says no. Studies that show benefit are in men with confirmed low testosterone, often with hypogonadal symptoms. In men with normal levels, testosterone produces no antidepressant effect, and supraphysiologic levels can worsen mood, raise hematocrit, and bring other risks without an offsetting benefit.

How long does testosterone augmentation take to show an effect?

In the studies that show benefit, mood improvement typically emerges over 8 to 12 weeks, alongside improvements in energy and libido. If there’s no clinically meaningful change at three months in a man with confirmed low T who’s been brought into the normal range, the augmentation isn’t working and the plan needs revisiting.

Can I take testosterone with my SSRI?

There’s no direct pharmacologic interaction that prohibits the combination, and the literature on SSRI-refractory hypogonadal men specifically tested adding testosterone to an existing antidepressant. The clinical decision rests on whether testosterone is actually indicated, which depends on lab values and symptoms rather than on the SSRI itself.

What’s the difference between TRT and testosterone augmentation?

TRT is the treatment of confirmed hypogonadism. Testosterone augmentation for depression is the same medical treatment, framed by its goal: using TRT in a man whose depression is incompletely treated, with the expectation that correcting the deficiency may improve mood as part of the broader response. The medication is the same; the indication and the monitoring focus differ.

Is testosterone augmentation safe long-term?

With appropriate monitoring of hematocrit, lipids, prostate markers, and other parameters, long-term testosterone therapy in confirmed hypogonadism is reasonable. The TRAVERSE trial provided reassurance on cardiovascular safety in the population it studied. Fertility suppression and the need for ongoing monitoring don’t go away, which is why this is best managed by a clinician with the time and incentive to track it properly.

Monthly plans cover Dr. Baghel’s clinical services only (evaluation, monitoring, medication management, ongoing care). Labs and medications are paid separately by the patient. This article describes off-label use of testosterone in the context of depression with confirmed hypogonadism; testosterone is FDA-approved for the treatment of hypogonadism, not for depression. This article is for educational purposes only and is not medical advice. If you are in crisis or thinking about harming yourself, call or text 988 to reach the Suicide and Crisis Lifeline. Do not start, stop, or change any medication or hormone therapy without speaking to your own clinician.

References

1. Walther A, Breidenstein J, Miller R. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76(1):31-40. PMID: 30427999.
2. Pope HG, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(1):105-111. PMID: 12505808.
3. Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry. 2009;70(7):1009-1016. PMID: 19653976.
4. Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord. 1998;48(2-3):157-161. PMID: 9543205.
5. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry. 2004;61(2):162-167. PMID: 14757592.
6. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364.
7. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. PMID: 37326322.
8. U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. FDA Drug Safety Communication.